Medication overuse and drug addiction: a narrative review from addiction perspective.
Dependence
Drug abuse
Migraine
Substance abuse
Vulnerability
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
28 Apr 2021
28 Apr 2021
Historique:
received:
22
12
2020
accepted:
12
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Chronic headache is particularly prevalent in migraineurs and it can progress to a condition known as medication overuse headache (MOH). MOH is a secondary headache caused by overuse of analgesics or other medications such as triptans to abort acute migraine attacks. The worsening of headache symptoms associated with medication overuse (MO) generally ameliorates following interruption of regular medication use, although the primary headache symptoms remain unaffected. MO patients may also develop certain behaviors such as ritualized drug administration, psychological drug attachment, and withdrawal symptoms that have been suggested to correlate with drug addiction. Although several reviews have been performed on this topic, to the authors best knowledge none of them have examined this topic from the addiction point of view. Therefore, we aimed to identify features in MO and drug addiction that may correlate. We initiate the review by introducing the classes of analgesics and medications that can cause MOH and those with high risk to produce MO. We further compare differences between sensitization resulting from MO and from drug addiction, the neuronal pathways that may be involved, and the genetic susceptibility that may overlap between the two conditions. Finally, ICHD recommendations to treat MOH will be provided herein.
Identifiants
pubmed: 33910499
doi: 10.1186/s10194-021-01224-8
pii: 10.1186/s10194-021-01224-8
pmc: PMC8080402
doi:
Substances chimiques
Analgesics
0
Tryptamines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Commentaires et corrections
Type : ErratumIn
Références
G.B.D.H (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol 17(11):954–976. https://doi.org/10.1016/S1474-4422(18)30322-3
doi: 10.1016/S1474-4422(18)30322-3
Steiner TJ et al (2020) Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137. https://doi.org/10.1186/s10194-020-01208-0
doi: 10.1186/s10194-020-01208-0
pubmed: 7708887
pmcid: 7708887
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 2018. 38(1): p. 1–211 DOI: https://doi.org/10.1177/0333102417738202
May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12(8):455–464. https://doi.org/10.1038/nrneurol.2016.93
doi: 10.1038/nrneurol.2016.93
Negro A, Rocchietti-March M, Fiorillo M, Martelletti P (2011) Chronic migraine: current concepts and ongoing treatments. Eur Rev Med Pharmacol Sci 15(12):1401–1420
Wakerley BR (2019) Medication-overuse headache. Pract Neurol 19(5):399–403. https://doi.org/10.1136/practneurol-2018-002048
doi: 10.1136/practneurol-2018-002048
Russell MB (2019) Epidemiology and management of medication-overuse headache in the general population. Neurol Sci 40(Suppl 1):23–26. https://doi.org/10.1007/s10072-019-03812-8
doi: 10.1007/s10072-019-03812-8
Martelletti P (2018) The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine. J Headache Pain 19(1):2. https://doi.org/10.1186/s10194-017-0830-2
doi: 10.1186/s10194-017-0830-2
pubmed: 5762616
pmcid: 5762616
Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, Toom K, Vandervorst F, Quintana S, Paemeleire K, Katsarava Z (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 19(1):50. https://doi.org/10.1186/s10194-018-0875-x
doi: 10.1186/s10194-018-0875-x
pubmed: 6043466
pmcid: 6043466
Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12(10):575–583. https://doi.org/10.1038/nrneurol.2016.124
doi: 10.1038/nrneurol.2016.124
pubmed: 27615418
pmcid: 27615418
Calabresi P, Cupini LM (2005) Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci 26(2):62–68. https://doi.org/10.1016/j.tips.2004.12.008
doi: 10.1016/j.tips.2004.12.008
pubmed: 15681022
pmcid: 15681022
Ong JJY, De Felice M (2018) Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics 15(2):274–290. https://doi.org/10.1007/s13311-017-0592-1
doi: 10.1007/s13311-017-0592-1
pubmed: 29235068
pmcid: 29235068
Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain 115(1–2):1–4. https://doi.org/10.1016/j.pain.2005.03.008
doi: 10.1016/j.pain.2005.03.008
pubmed: 15836963
pmcid: 15836963
Tfelt-Hansen P et al (2000) Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 123(Pt 1):9–18. https://doi.org/10.1093/brain/123.1.9
doi: 10.1093/brain/123.1.9
pubmed: 10611116
pmcid: 10611116
Tfelt-Hansen P (2020) Pharmacological strategies to treat attacks of episodic migraine in adults. Expert Opin Pharmacother 22(3):1–12. https://doi.org/10.1080/14656566.2020.1828347
doi: 10.1080/14656566.2020.1828347
Silberstein SD, Stirpe JC (2014) COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 15(13):1863–1874. https://doi.org/10.1517/14656566.2014.937704
doi: 10.1517/14656566.2014.937704
pubmed: 25010639
pmcid: 25010639
Graham GG, Scott KF (2003) Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology 11(4):401–413. https://doi.org/10.1163/156856003322699573
doi: 10.1163/156856003322699573
pubmed: 15035793
pmcid: 15035793
Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18(4 Suppl):S3–S13. https://doi.org/10.1097/00002508-200207001-00002
Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT (2016) Nociceptin/Orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev 68(2):419–457. https://doi.org/10.1124/pr.114.009209
doi: 10.1124/pr.114.009209
pubmed: 26956246
pmcid: 26956246
De Felice M, Ossipov MH, Porreca F (2011) Update on medication-overuse headache. Curr Pain Headache Rep 15(1):79–83. https://doi.org/10.1007/s11916-010-0155-1
doi: 10.1007/s11916-010-0155-1
pubmed: 3780979
pmcid: 3780979
Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC (2002) Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59(7):1011–1014. https://doi.org/10.1212/wnl.59.7.1011
doi: 10.1212/wnl.59.7.1011
Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9(4):391–401. https://doi.org/10.1016/S1474-4422(10)70008-9
doi: 10.1016/S1474-4422(10)70008-9
Scher AI, Lipton RB, Stewart WF, Bigal M (2010) Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia 30(3):321–328. https://doi.org/10.1111/j.1468-2982.2009.01913.x
doi: 10.1111/j.1468-2982.2009.01913.x
Katsarava Z, Diener HC, Limmroth V (2001) Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf 24(12):921–927. https://doi.org/10.2165/00002018-200124120-00005
doi: 10.2165/00002018-200124120-00005
van Amsterdam J, van den Brink W (2015) The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev 8(1):3–14. https://doi.org/10.2174/187447370801150611184218
doi: 10.2174/187447370801150611184218
Weisberg DF, Becker WC, Fiellin DA, Stannard C (2014) Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. Int J Drug Policy 25(6):1124–1130. https://doi.org/10.1016/j.drugpo.2014.07.009
doi: 10.1016/j.drugpo.2014.07.009
Soelberg CD, Brown RE Jr, du Vivier D, Meyer JE, Ramachandran BK (2017) The US opioid crisis: current federal and state legal issues. Anesth Analg 125(5):1675–1681. https://doi.org/10.1213/ANE.0000000000002403
doi: 10.1213/ANE.0000000000002403
Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A (2019) Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. Lancet Public Health 4(10):e498–e505. https://doi.org/10.1016/S2468-2667(19)30128-8
doi: 10.1016/S2468-2667(19)30128-8
Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P (2019) Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain 20(1):57. https://doi.org/10.1186/s10194-018-0899-2
doi: 10.1186/s10194-018-0899-2
pubmed: 6734476
pmcid: 6734476
Van Etten ML, Anthony JC (1999) Comparative epidemiology of initial drug opportunities and transitions to first use: marijuana, cocaine, hallucinogens and heroin. Drug Alcohol Depend 54(2):117–125. https://doi.org/10.1016/s0376-8716(98)00151-3
doi: 10.1016/s0376-8716(98)00151-3
DuPont RL, Han B, Shea CL, Madras BK (2018) Drug use among youth: national survey data support a common liability of all drug use. Prev Med 113:68–73. https://doi.org/10.1016/j.ypmed.2018.05.015
doi: 10.1016/j.ypmed.2018.05.015
Delgado-Lobete, L., Montes-Montes R., Vila-Paz A., Cruz-Valiño J.M., Gándara-Gafo B., Talavera-Valverde M.Á., Santos-del-Riego S., Individual and Environmental Factors Associated with Tobacco Smoking, Alcohol Abuse and Illegal Drug Consumption in University Students: A Mediating Analysis. Int J Environ Res Public Health, 2020. 17(9) DOI: https://doi.org/10.3390/ijerph17093019 , 17, 9
Robinson TE, Berridge KC (2008) Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond Ser B Biol Sci 363(1507):3137–3146. https://doi.org/10.1098/rstb.2008.0093
doi: 10.1098/rstb.2008.0093
Takahashi TT, Vengeliene V, Enkel T, Reithofer S, Spanagel R (2019) Pavlovian to instrumental transfer responses do not correlate with addiction-like behavior in rats. Front Behav Neurosci 13:129. https://doi.org/10.3389/fnbeh.2019.00129
doi: 10.3389/fnbeh.2019.00129
pubmed: 6591257
pmcid: 6591257
Association, A.P., Diagnostic and statistical manual of mental disorders, 5th Edition. 2013, DOI: https://doi.org/10.1176/appi.books.9780890425596
de Boer I, van den Maagdenberg A, Terwindt GM (2019) Advance in genetics of migraine. Curr Opin Neurol 32(3):413–421. https://doi.org/10.1097/WCO.0000000000000687
doi: 10.1097/WCO.0000000000000687
pubmed: 6522206
pmcid: 6522206
Sutherland HG, Albury CL, Griffiths LR (2019) Advances in genetics of migraine. J Headache Pain 20(1):72. https://doi.org/10.1186/s10194-019-1017-9
doi: 10.1186/s10194-019-1017-9
pubmed: 6734342
pmcid: 6734342
Westergaard ML, Glümer C, Hansen EH, Jensen RH (2014) Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 155(10):2005–2013. https://doi.org/10.1016/j.pain.2014.07.002
doi: 10.1016/j.pain.2014.07.002
Jonsson P, Linde M, Hensing G, Hedenrud T (2012) Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain 13(4):281–290. https://doi.org/10.1007/s10194-012-0432-y
doi: 10.1007/s10194-012-0432-y
pubmed: 3356474
pmcid: 3356474
Atasoy HT, Unal AE, Atasoy N, Emre U, Sumer M (2005) Low income and education levels may cause medication overuse and chronicity in migraine patients. Headache 45(1):25–31. https://doi.org/10.1111/j.1526-4610.2005.05006.x
doi: 10.1111/j.1526-4610.2005.05006.x
Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M (2005) Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain 9(3):285–291. https://doi.org/10.1016/j.ejpain.2004.07.006
doi: 10.1016/j.ejpain.2004.07.006
Radat F, Creac'h C, Swendsen JD, Lafittau M, Irachabal S, Dousset V, Henry P (2005) Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 25(7):519–522. https://doi.org/10.1111/j.1468-2982.2005.00910.x
doi: 10.1111/j.1468-2982.2005.00910.x
Everitt B (1997) Craving cocaine cues: cognitive neuroscience meets drug addiction research. Trends Cogn Sci 1(1):1–2. https://doi.org/10.1016/S1364-6613(97)01009-7
doi: 10.1016/S1364-6613(97)01009-7
Louter MA, Bosker JE, van Oosterhout WPJ, van Zwet EW, Zitman FG, Ferrari MD, Terwindt GM (2013) Cutaneous allodynia as a predictor of migraine chronification. Brain 136(11):3489–3496. https://doi.org/10.1093/brain/awt251
doi: 10.1093/brain/awt251
Camarini R, Pautassi RM (2016) Behavioral sensitization to ethanol: neural basis and factors that influence its acquisition and expression. Brain Res Bull 125:53–78. https://doi.org/10.1016/j.brainresbull.2016.04.006
doi: 10.1016/j.brainresbull.2016.04.006
Strakowski SM, Sax KW, Setters MJ, Keck PE Jr (1996) Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans. Biol Psychiatry 40(9):872–880. https://doi.org/10.1016/0006-3223(95)00497-1
doi: 10.1016/0006-3223(95)00497-1
Kalivas PW, Duffy P (1988) Effects of daily cocaine and morphine treatment on somatodendritic and terminal field dopamine release. J Neurochem 50(5):1498–1504. https://doi.org/10.1111/j.1471-4159.1988.tb03036.x
doi: 10.1111/j.1471-4159.1988.tb03036.x
Kuczenski R, Segal D (1989) Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9(6):2051–2065. https://doi.org/10.1523/jneurosci.09-06-02051.1989
doi: 10.1523/jneurosci.09-06-02051.1989
pubmed: 6569745
pmcid: 6569745
Leyton M (2007) Conditioned and sensitized responses to stimulant drugs in humans. Prog Neuro-Psychopharmacol Biol Psychiatry 31(8):1601–1613. https://doi.org/10.1016/j.pnpbp.2007.08.027
doi: 10.1016/j.pnpbp.2007.08.027
Sugiyama E, Kondo T, Kuzumaki N, Honda K, Yamanaka A, Narita M, Suematsu M, Sugiura Y (2019) Mechanical allodynia induced by optogenetic sensory nerve excitation activates dopamine signaling and metabolism in medial nucleus accumbens. Neurochem Int 129:104494. https://doi.org/10.1016/j.neuint.2019.104494
doi: 10.1016/j.neuint.2019.104494
DaSilva AF, Nascimento TD, Jassar H, Heffernan J, Toback RL, Lucas S, DosSantos MF, Bellile EL, Boonstra PS, Taylor JMG, Casey KL, Koeppe RA, Smith YR, Zubieta JK (2017) Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo. Neurology 88(17):1634–1641. https://doi.org/10.1212/wnl.0000000000003861
doi: 10.1212/wnl.0000000000003861
pubmed: 5405765
pmcid: 5405765
Peroutka SJ, Wilhoit T, Jones K (1997) Clinical susceptibility to migraine with aura is modified by dopamine D<sub>2</sub> receptor (DRD2) <em>Nco</em> I alleles. Neurology 49(1):201–206. https://doi.org/10.1212/wnl.49.1.201
doi: 10.1212/wnl.49.1.201
Wöber C, Brücke T, Wöber-Bingöl C, Asenbaum S, Wessely P, Podreka I (1994) Dopamine D2 receptor blockade and Antimigraine action of Flunarizine. Cephalalgia 14(3):235–240. https://doi.org/10.1046/j.1468-2982.1994.014003235.x
doi: 10.1046/j.1468-2982.1994.014003235.x
Akerman S, Goadsby P (2007) Dopamine and migraine: biology and clinical implications. Cephalalgia 27(11):1308–1314. https://doi.org/10.1111/j.1468-2982.2007.01478.x
doi: 10.1111/j.1468-2982.2007.01478.x
Martikainen IK, Nuechterlein EB, Pecina M, Love TM, Cummiford CM, Green CR, Stohler CS, Zubieta JK (2015) Chronic Back pain is associated with alterations in dopamine neurotransmission in the ventral striatum. J Neurosci 35(27):9957–9965. https://doi.org/10.1523/JNEUROSCI.4605-14.2015
doi: 10.1523/JNEUROSCI.4605-14.2015
pubmed: 4495244
pmcid: 4495244
Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8(11):1481–1489. https://doi.org/10.1038/nn1579
doi: 10.1038/nn1579
Everitt BJ, Robbins TW (2016) Drug addiction: updating actions to habits to compulsions ten years on. Annu Rev Psychol 67(1):23–50. https://doi.org/10.1146/annurev-psych-122414-033457
doi: 10.1146/annurev-psych-122414-033457
Berridge KC, Robinson TE (2016) Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol 71(8):670–679. https://doi.org/10.1037/amp0000059
doi: 10.1037/amp0000059
pubmed: 5171207
pmcid: 5171207
Hyman SE, Malenka RC (2001) Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2(10):695–703. https://doi.org/10.1038/35094560
doi: 10.1038/35094560
Chiang C-C, Schwedt TJ, Wang SJ, Dodick DW (2016) Treatment of medication-overuse headache: a systematic review. Cephalalgia 36(4):371–386. https://doi.org/10.1177/0333102415593088
doi: 10.1177/0333102415593088
Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T (2019) Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 18(9):891–902. https://doi.org/10.1016/S1474-4422(19)30146-2
doi: 10.1016/S1474-4422(19)30146-2
Hunt WA, Bespalec DA (1974) Relapse rates after treatment for heroin addiction. J Commun Psychol 2(1):85–87. https://doi.org/10.1002/1520-6629(197401)2:1<85::AID-JCOP2290020130>3.0.CO;2-B
doi: 10.1002/1520-6629(197401)2:1<85::AID-JCOP2290020130>3.0.CO;2-B
Hunt WA, General WR (1973) Relapse rates after treatment for alcoholism. J Commun Psychol 1(1):66–68. https://doi.org/10.1002/1520-6629(197301)1:1<66::AID-JCOP2290010119>3.0.CO;2-R
doi: 10.1002/1520-6629(197301)1:1<66::AID-JCOP2290010119>3.0.CO;2-R
Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V (2005) Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 25(1):12–15. https://doi.org/10.1111/j.1468-2982.2004.00789.x
doi: 10.1111/j.1468-2982.2004.00789.x
Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, Grazzi L, Usai S, D'Amico D (2017) Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: a longitudinal observational study. Headache 57(1):60–70. https://doi.org/10.1111/head.12979
doi: 10.1111/head.12979
Rossi P, Faroni J, Nappi G (2008) Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 28(11):1196–1200. https://doi.org/10.1111/j.1468-2982.2008.01659.x
doi: 10.1111/j.1468-2982.2008.01659.x
Becerra L, Bishop J, Barmettler G, Xie Y, Navratilova E, Porreca F, Borsook D (2016) Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas. J Neurophysiol 115(1):208–217. https://doi.org/10.1152/jn.00632.2015
doi: 10.1152/jn.00632.2015
De Felice M, Ossipov MH, Porreca F (2011) Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol 24(3):193–196. https://doi.org/10.1097/WCO.0b013e328346af25
doi: 10.1097/WCO.0b013e328346af25
pubmed: 5690482
pmcid: 5690482
De Felice M et al (2010) Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 133(Pt 8):2475–2488. https://doi.org/10.1093/brain/awq159
doi: 10.1093/brain/awq159
pubmed: 3139937
pmcid: 3139937
Burstein R (2001) Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2–3):107–110. https://doi.org/10.1016/s0304-3959(00)00478-4
doi: 10.1016/s0304-3959(00)00478-4
Strassman AM, Raymond SA, Burstein R (1996) Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384(6609):560–564. https://doi.org/10.1038/384560a0
doi: 10.1038/384560a0
De Felice M et al (2010) Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 67(3):325–337. https://doi.org/10.1002/ana.21897
doi: 10.1002/ana.21897
pubmed: 5690477
pmcid: 5690477
Gardell, L.R., et al., Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci, 2002. 22(15): p. 6747–6755 DOI: 20026648
Bongsebandhu-phubhakdi S, Srikiatkhachorn A (2012) Pathophysiology of medication-overuse headache: implications from animal studies. Curr Pain Headache Rep 16(1):110–115. https://doi.org/10.1007/s11916-011-0234-y
doi: 10.1007/s11916-011-0234-y
Ayzenberg I, Oberman M, Leineweber K, Franke L, Yoon MS, Diener HC, Katsarava Z (2008) Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans. J Headache Pain 9(2):109–112. https://doi.org/10.1007/s10194-008-0019-9
doi: 10.1007/s10194-008-0019-9
pubmed: 3476187
pmcid: 3476187
Hering R, Glover V, Pattichis K, Catarci T, Steiner TJ (1993) 5HT in migraine patients with medication-induced headache. Cephalalgia 13(6):410–412. https://doi.org/10.1046/j.1468-2982.1993.1306410.x
doi: 10.1046/j.1468-2982.1993.1306410.x
Srikiatkhachorn A, Anthony M (1996) Platelet serotonin in patients with analgesic-induced headache. Cephalalgia 16(6):423–426. https://doi.org/10.1046/j.1468-2982.1996.1606423.x
Srikiatkhachorn A, Puangniyom S, Govitrapong P (1998) Plasticity of 5-HT serotonin receptor in patients with analgesic-induced transformed migraine. Headache 38(7):534–539. https://doi.org/10.1046/j.1526-4610.1998.3807534.x
doi: 10.1046/j.1526-4610.1998.3807534.x
Srikiatkhachorn A, Tarasub N, Govitrapong P (2000) Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 40(5):343–350. https://doi.org/10.1046/j.1526-4610.2000.00052.x
doi: 10.1046/j.1526-4610.2000.00052.x
Supornsilpchai W, le Grand SM, Srikiatkhachorn A (2010) Involvement of pro-nociceptive 5-HT2A receptor in the pathogenesis of medication-overuse headache. Headache 50(2):185–197. https://doi.org/10.1111/j.1526-4610.2009.01591.x
doi: 10.1111/j.1526-4610.2009.01591.x
pubmed: 20039957
pmcid: 20039957
Loggia ML, Berna C, Kim J, Cahalan CM, Gollub RL, Wasan AD, Harris RE, Edwards RR, Napadow V (2014) Disrupted brain circuitry for pain-related reward/punishment in fibromyalgia. Arthritis Rheumatol 66(1):203–212. https://doi.org/10.1002/art.38191
doi: 10.1002/art.38191
pubmed: 24449585
pmcid: 24449585
Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, Bushnell MC, Chizh BA (2007) Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 25(12):3576–3582. https://doi.org/10.1111/j.1460-9568.2007.05623.x
doi: 10.1111/j.1460-9568.2007.05623.x
pubmed: 17610577
pmcid: 17610577
Anselmi B, Baldi E, Casacci F, Salmon S (1980) Endogenous opioids in cerebrospinal fluid and blood in idiopathic headache sufferers. Headache 20(6):294–299. https://doi.org/10.1111/j.1526-4610.1980.hed2006294.x
doi: 10.1111/j.1526-4610.1980.hed2006294.x
pubmed: 7216749
pmcid: 7216749
Baliki MN, Geha PY, Fields HL, Apkarian AV (2010) Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain. Neuron 66(1):149–160. https://doi.org/10.1016/j.neuron.2010.03.002
doi: 10.1016/j.neuron.2010.03.002
pubmed: 2873199
pmcid: 2873199
Jarcho JM, Mayer EA, Jiang ZK, Feier NA, London ED (2012) Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction. Pain 153(4):744–754. https://doi.org/10.1016/j.pain.2012.01.002
doi: 10.1016/j.pain.2012.01.002
Barbanti P, Guadagni F, de Marchis ML, Ialongo C, Egeo G, Fofi L, Aurilia C, Lovero D, Della-Morte D, Ferroni P, Palmirotta R (2019) Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine. Neurol Sci 40(8):1717–1724. https://doi.org/10.1007/s10072-019-03865-9
doi: 10.1007/s10072-019-03865-9
Cargnin S, Pautasso C, Viana M, Sances G, Mittino D, Cantello R, Tassorelli C, Nappi G, Terrazzino S (2015) Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache. Headache 55(5):658–668. https://doi.org/10.1111/head.12559
doi: 10.1111/head.12559
Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278(5335):52–58. https://doi.org/10.1126/science.278.5335.52
doi: 10.1126/science.278.5335.52
Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24(2):97–129. https://doi.org/10.1016/S0893-133X(00)00195-0
doi: 10.1016/S0893-133X(00)00195-0
Volkow ND, Fowler JS, Wang GJ (1999) Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 13(4):337–345. https://doi.org/10.1177/026988119901300406
doi: 10.1177/026988119901300406
pubmed: 10667609
pmcid: 10667609
Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJH, Comings DE (1995) Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenet Genomics 5(3):121–141. https://doi.org/10.1097/00008571-199506000-00001
doi: 10.1097/00008571-199506000-00001
Clarke, T.-K., et al., The Dopamine Receptor D2 (DRD2) SNP rs1076560 is Associated with Opioid Addiction. Annals of Human Genetics, 2014. 78(1): p. 33–39 DOI: https://doi.org/10.1111/ahg.12046
Groman, S.M. and J.D. Jentsch, Cognitive control and the dopamine D2-like receptor: a dimensional understanding of addiction. Depression Anxiety, 2012. 29(4): p. 295–306 DOI: https://doi.org/ https://doi.org/10.1002/da.20897
Jorm AF, Henderson AS, Jacomb PA, Christensen H, Korten AE, Rodgers B, Tan X, Easteal S (2000) Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 96(3):331–334. https://doi.org/10.1002/1096-8628(20000612)96:3<331::aid-ajmg19>3.0.co;2-0
doi: 10.1002/1096-8628(20000612)96:3<331::aid-ajmg19>3.0.co;2-0
pubmed: 10898910
pmcid: 10898910
Laine TP, Ahonen A, Räsänen P, Tiihonen J (2001) Dopamine transporter density and novelty seeking among alcoholics. J Addict Dis 20(4):91–96. https://doi.org/10.1300/j069v20n04_08
doi: 10.1300/j069v20n04_08
pubmed: 11760929
pmcid: 11760929
Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B, Boyd NR, Shields PG (1999) Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18(1):14–20. https://doi.org/10.1037/0278-6133.18.1.14
doi: 10.1037/0278-6133.18.1.14
pubmed: 9925041
pmcid: 9925041
Schmidt LG, Harms H, Kuhn S, Rommelspacher H, Sander T (1998) Modification of alcohol withdrawal by the A9 allele of the dopamine transporter gene. Am J Psychiatry 155(4):474–478. https://doi.org/10.1176/ajp.155.4.474
doi: 10.1176/ajp.155.4.474
pubmed: 9545991
pmcid: 9545991
Ferraro, S., et al., In Medication-Overuse Headache, fMRI Shows Long-Lasting Dysfunction in Midbrain Areas. Headache, 2012. 52(10): p. 1520–1534 DOI: https://doi.org/ https://doi.org/10.1111/j.1526-4610.2012.02276.x
Riederer F, Marti M, Luechinger R, Lanzenberger R, von Meyenburg J, Gantenbein AR, Pirrotta R, Gaul C, Kollias S, Sándor PS (2012) Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety. World J Biol Psychiatry 13(7):517–525. https://doi.org/10.3109/15622975.2012.665175
doi: 10.3109/15622975.2012.665175
pubmed: 22746999
pmcid: 22746999
Lai TH, Chou KH, Fuh JL, Lee PL, Kung YC, Lin CP, Wang SJ (2016) Gray matter changes related to medication overuse in patients with chronic migraine. Cephalalgia 36(14):1324–1333. https://doi.org/10.1177/0333102416630593
doi: 10.1177/0333102416630593
Chong CD, Schwedt TJ, Hougaard A (2019) Brain functional connectivity in headache disorders: a narrative review of MRI investigations. J Cereb Blood Flow Metab 39(4):650–669. https://doi.org/10.1177/0271678X17740794
doi: 10.1177/0271678X17740794
Fumal A, Laureys S, di Clemente L, Boly M, Bohotin V, Vandenheede M, Coppola G, Salmon E, Kupers R, Schoenen J (2006) Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 129(Pt 2):543–550. https://doi.org/10.1093/brain/awh691
doi: 10.1093/brain/awh691
Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L (2018) Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia 38(2):225–236. https://doi.org/10.1177/0333102417737779
doi: 10.1177/0333102417737779
Engelstoft IMS, Carlsen LN, Munksgaard SB, Nielsen M, Jensen RH, Bendtsen L (2019) Complete withdrawal is the most feasible treatment for medication-overuse headache: a randomized controlled open-label trial. Eur J Pain 23(6):1162–1170. https://doi.org/10.1002/ejp.1383
doi: 10.1002/ejp.1383
Evers S, Jensen R, S. European Federation Of neurological (2011) Treatment of medication overuse headache--guideline of the EFNS headache panel. Eur J Neurol 18(9):1115–1121. https://doi.org/10.1111/j.1468-1331.2011.03497.x
doi: 10.1111/j.1468-1331.2011.03497.x
de Goffau MJ, Klaver ARE, Willemsen MG, Bindels PJE, Verhagen AP (2017) The effectiveness of treatments for patients with medication overuse headache: a systematic review and meta-analysis. J Pain 18(6):615–627. https://doi.org/10.1016/j.jpain.2016.12.005
doi: 10.1016/j.jpain.2016.12.005
Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, Kristoffersen ES, Tassorelli C, Ryliskiene K, Petersen JA (2020) European academy of neurology guideline on the management of medication-overuse headache. Eur J Neurol 27(7):1102–1116. https://doi.org/10.1111/ene.14268
doi: 10.1111/ene.14268
Tiseo C, Ornello R, Pistoia F, Sacco S (2019) How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain 20(1):49. https://doi.org/10.1186/s10194-019-1000-5
doi: 10.1186/s10194-019-1000-5
pubmed: 6734464
pmcid: 6734464
Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92(20):e2309–e2320. https://doi.org/10.1212/WNL.0000000000007497
doi: 10.1212/WNL.0000000000007497
pubmed: 6598821
pmcid: 6598821
Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM (2020) Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia:333102420966658. https://doi.org/10.1177/0333102420966658
Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114. https://doi.org/10.1186/s10194-020-01173-8
doi: 10.1186/s10194-020-01173-8
pubmed: 7507645
pmcid: 7507645
Pijpers JA, Kies DA, Louter MA, van Zwet EW, Ferrari MD, Terwindt GM (2019) Acute withdrawal and botulinum toxin a in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain 142(5):1203–1214. https://doi.org/10.1093/brain/awz052
doi: 10.1093/brain/awz052
pubmed: 6511115
pmcid: 6511115
Hagen K, Albretsen C, Vilming ST, Salvesen R, Grøning M, Helde G, Gravdahl G, Zwart JA, Stovner LJ (2009) Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia 29(2):221–232. https://doi.org/10.1111/j.1468-2982.2008.01711.x
doi: 10.1111/j.1468-2982.2008.01711.x
Negro A, Curto M, Lionetto L, Guerzoni S, Pini LA, Martelletti P (2017) A critical evaluation on MOH current treatments. Curr Treat Options Neurol 19(9):32. https://doi.org/10.1007/s11940-017-0465-2
doi: 10.1007/s11940-017-0465-2
Grazzi L, Bussone G (2011) What future for treatment of chronic migraine with medication overuse? Neurol Sci 32(Suppl 1):S19–S22. https://doi.org/10.1007/s10072-011-0553-0
doi: 10.1007/s10072-011-0553-0
Grazzi L, Andrasik F, D'Amico D, Leone M, Usai S, Kass SJ, Bussone G (2002) Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 42(6):483–490. https://doi.org/10.1046/j.1526-4610.2002.02123.x
doi: 10.1046/j.1526-4610.2002.02123.x
Andrasik F, Buse DC, Grazzi L (2009) Behavioral medicine for migraine and medication overuse headache. Curr Pain Headache Rep 13(3):241–248. https://doi.org/10.1007/s11916-009-0041-x
doi: 10.1007/s11916-009-0041-x
Sancisi E, Rausa M, Zanigni S, Cevoli S, Pala AN, Nicodemo M, Grimaldi D, Montagna P, Cortelli P, Pierangeli G (2009) Self-help group and medication overuse headache: preliminary data. Neurol Sci 30(6):459–463. https://doi.org/10.1007/s10072-009-0131-x
doi: 10.1007/s10072-009-0131-x
Radat F, Chanraud S, di Scala G, Dousset V, Allard M (2013) Psychological and neuropsychological correlates of dependence-related behaviour in medication overuse headaches: a one year follow-up study. J Headache Pain 14(1):59. https://doi.org/10.1186/1129-2377-14-59
doi: 10.1186/1129-2377-14-59
pubmed: 3706211
pmcid: 3706211
Volkow ND, Boyle M (2018) Neuroscience of addiction: relevance to prevention and treatment. Am J Psychiatry 175(8):729–740. https://doi.org/10.1176/appi.ajp.2018.17101174
doi: 10.1176/appi.ajp.2018.17101174
pubmed: 29690790
pmcid: 29690790